Background: Despite effective screening and vaccination programs, Europe’s cervical cancer incidence remains above the WHO elimination target (11 vs. 4 cases per 100,000 persons), with substantial inter-country variability ranging from 3 to 26 per 100,000 person-years. The European Commission (EC) calls for high screening coverage and coordinated, standardised, patient-centred prevention strategies.

Objective: To integrate evidence-based guidelines with a harmonised Quality Assurance (QA) scheme to support equitable and high-quality cervical cancer prevention across Europe.

Methods: The European Commission Initiative for Cervical Cancer Working Group (EC-CvC WG) developed and prioritized healthcare questions, appraised the outcomes of systematically conducted evidence syntheses, assessed the certainty of evidence using the GRADE approach and developed recommendations. Explicit magnitude of effect thresholds were developed to ensure consistency and transparency in judgments. Under a risk-stratified approach, management decisions were guided by the principle of “equal risk, equal management”, with clinical recommendations aligned to cervical intraepithelial neoplasia grade 3 or worse (CIN3+) risk categories. In parallel, quality indicators relevant to each recommendation were systematically identified, appraised, and will be incorporated into the QA framework along critical points of the patient pathway. All recommendations, evidence-to-decision (EtD) tables, and expert judgments are publicly available in both technical and lay formats.

Results: Priority health questions and critical points along the patient pathway were identified to inform both recommendations and quality monitoring. To date 16 recommendation have been developed along with 22 screening indicators which are currently under evaluation. Decision thresholds were anchored to the WHO elimination targets, EU average incidence, and screening programme reports where feasible. Risk stratification analysis distinguishes three zones based on the 5-year cumulative risk of CIN3+ (<1%, 1–<10%, ≥10%), guiding return to routine screening, surveillance, or referral to colposcopy, respectively. The QA scheme focuses on key, and often insufficiently monitored, steps in the patient journey and includes tools for compliance assessment. Accreditation under EC Regulation No 765/2008 supports consistency across settings. The web-based platform facilitates transparency, accessibility, and timely updates.

Conclusion: The EC-CvC provides a novel, evidence-based and patient-centred framework that integrates guideline recommendations with quality assurance for cervical cancer prevention. By strengthening transparency, consistency, and equity, it supports high-quality implementation across diverse European settings.